1stline Study Capecitabine Administered on Continuous Way Plus Oxaliplatin&Bevacizumab Every 2weeks in Metastatic CCR.
收藏NIAID Data Ecosystem2026-03-06 收录
官方服务：
资源简介：
The purpose of this study is to determinate progression free survival after 9 months of treatment.
创建时间：
2006-06-15
